Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
批准号:
8523895
负责人:
Lianwang Guo
金额:
$31.96万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-01 至 2017-07-31
关键词:
AcuteApoptosisApoptoticBlindnessCell DeathCell TransplantsCellsCessation of lifeCharacteristicsChronicDataDegenerative DisorderDisease modelEnvironmentEventExposure toEyeEye diseasesGenesGlaucomaGoalsHumanInvestigationKnock-outLeadLightMediatingMembrane ProteinsMethodsModelingMolecular ChaperonesMorphologyMusMutationNerve CrushNerve DegenerationNeurodegenerative DisordersNeuroprotective AgentsOpsinOptic NerveOxidative StressOxygenPhotoreceptorsPopulationProcessPropertyProteinsReactive Oxygen SpeciesReportingRetinaRetinalRetinal DegenerationRetinal Ganglion CellsRetinal PhotoreceptorsRetinitis PigmentosaRoleStem cellsSubfamily lentivirinaeTechniquesTestingTherapeuticTransgenic OrganismsTransplantationViral VectorVirusVisioncellular transductioneffective therapyefficacy testingganglion cellgene therapyhuman embryonic stem cellin vivomouse modelneuroprotectionnew therapeutic targetnoveloverexpressionpromoterprotective effectreceptorretinal rodssigma-1 receptorstem cell therapysubretinal injectiontherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Neurodegenerative eye diseases such as glaucoma cause blindness in a large population in the USA, yet effective treatments are lacking. The ultimate goal of this project is to develop new methods for rescue of retinal neurodegeneration by exploiting a unique endogenous neuroprotective agent, the ?1R chaperone, whose anti-apoptotic properties are being uncovered. Our in vivo studies suggest that the ? 1R is ROS (reactive oxygen species)-suppressing and is protective against retinal degeneration in ganglion cells as well as in photoreceptors. This project represents the first study to test the efficacy of
the ? 1R-mediated retinal neuroprotection by ? 1R gene therapy, by overexpressing the ? 1R in stem cell-derived photoreceptors to enhance their post-transplantation survival, and by using the sigma-1 receptor knock model (? 1ko) combined with the chronic DBA/2J glaucoma model or rd10 model. In Specific Aim 1, we will examine the impact of the absence of the ? 1R for the viability of ganglion cells and photoreceptors in vivo in the DBA/2J model of glaucoma and the rd10 model of RP, respectively. Since we have discovered that ganglion cells of the ? 1ko mice are more susceptible to retinal degeneration than the wild type in an acute model, we will further test our finding using a new model crossed with the ? 1ko and the chronic glaucoma model of DBA/2J. We will also extend our investigation into a neuroprotective role of the ? 1R in retinal photoreceptors, which has yet to be defined, in a new model that we have generated by crossing ¿1ko and rd10. Retinal ROS levels will be compared in the presence and absence of the ? 1R in these models. In Specific Aim 2, we will test ? 1R gene therapy for rescue of retinal degeneration using lentiviruses. To increase the ? 1R abundance in the retina, we will transduce the rd10 mouse photoreceptors with lentiviruses harboring the ? 1R gene and the Opsin promoter using a technique of subretinal injection. Retinal functions of the transgenic eye overexpressing the ? 1R will be compared to that injected with the ? 1R-negative mock virus. In Specific Aim 3, we will explore the neuroprotective effect of the ? 1R on the post-transplantation survival of stem cell-derived photoreceptors. In stem cell therapy, elevated oxidative stress due to the death of rods, which are active major consumers of oxygen in the retina, imposes detrimental threat to the survival of transplanted photoreceptors. We will overexpress the ? 1R in human embryonic stem cell-derived photoreceptors to enhance their survival after transplantation into the rd10 retina. The pro-survival effect of the ? 1R on transplanted photoreceptors will be assessed in comparison to the control transplant cells that are transduced with the ? 1R-negative mock virus. Ultimately, our finding will lead to new ? 1R-targeted therapeutic strategies for rescue of the devastating retinal neurodegenerative diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Master epigenetic regulators and retinal degenerative disease
-
批准号:10306197
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2021
-
负责人:Lianwang Guo
-
依托单位:
Master epigenetic regulators and retinal degenerative disease
-
批准号:10132335
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2021
-
负责人:Lianwang Guo
-
依托单位:
Master epigenetic regulators and retinal degenerative disease
-
批准号:10376193
-
项目类别:
-
资助金额:$39.09万
-
财政年份:2021
-
负责人:Lianwang Guo
-
依托单位:
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery
-
批准号:10298010
-
项目类别:
-
资助金额:$31.49万
-
财政年份:2020
-
负责人:Lianwang Guo
-
依托单位:
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction
-
批准号:10305283
-
项目类别:
-
资助金额:$16.83万
-
财政年份:2020
-
负责人:Lianwang Guo
-
依托单位:
Master epigenetic regulators and retinal degenerative disease
-
批准号:9884774
-
项目类别:
-
资助金额:$3.84万
-
财政年份:2019
-
负责人:Lianwang Guo
-
依托单位:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
-
批准号:9513208
-
项目类别:
-
资助金额:$16.5万
-
财政年份:2012
-
负责人:Lianwang Guo
-
依托单位:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
-
批准号:8346582
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2012
-
负责人:Lianwang Guo
-
依托单位:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
-
批准号:8700417
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2012
-
负责人:Lianwang Guo
-
依托单位:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
-
批准号:9117592
-
项目类别:
-
资助金额:$17.14万
-
财政年份:2012
-
负责人:Lianwang Guo
-
依托单位:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
-
批准号:8895333
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2012
-
负责人:Lianwang Guo
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: